Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
AS03 is an **oil-in-water emulsion adjuvant** composed of squalene, DL-α-tocopherol (vitamin E), and polysorbate 80. It is not a molecular receptor or protein target but a pharmaceutical excipient designed to stimulate the innate immune system for enhanced vaccine efficacy. AS03 functions primarily by promoting antigen uptake and presentation by antigen-presenting cells and inducing local cytokine production, leading to improved and sustained adaptive immune responses dominated by Th2 polarization and robust memory B cell generation. Key mechanisms involve activation of NLRP3 and TLR signaling (with some pathway independence), modulation of chemokine/cytokine expression, and induction of ER stress responses in myeloid cells, ultimately driving enhanced antibody responses and the recruitment of immune effector cells. AS03 is licensed and widely used in pandemic influenza vaccines and increasingly investigated in emerging infectious disease vaccines, demonstrating good safety and immunogenicity profiles in clinical and preclinical studies [1][2][3][4][5][6]. **Note:** The query "Innate immune system stimulation via AS03 adjuvant" refers to a process or mechanism, not a canonical molecular target. AS03 is an adjuvant system, not a discrete receptor, enzyme, or classical therapeutic target. The correct way to structure information for later use is to list AS03 as an adjuvant excipient that acts on multiple innate immune pathways, not as a molecular target itself.
Facilitates antigen uptake and presentation by antigen-presenting cells (APCs) [1][2][3] Activates innate immune pathways (NLRP3 and TLR-pathways, with unique independence from ASC and MyD88) [2][3] Induces cytokine and chemokine secretion (e.g., IL-6, CCL2, CCL3, CXCL1) recruiting granulocytes and modulating adaptive and innate responses [2][3][6] Triggers ER stress and activates IRE1α/JNK signaling in myeloid cells (impacts T follicular helper cell response and antibody quality) [5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on AS03 adjuvant (AS03).